Adriaan Voors News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Adriaan voors. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Adriaan Voors Today - Breaking & Trending Today

Corteria Pharmaceuticals announces initiation of Phase 1 study to evaluate CRF2 agonist COR-1167 for treatment of worsening heart failure

Corteria Pharmaceuticals announces initiation of Phase 1 study to evaluate CRF2 agonist COR-1167 for treatment of worsening heart failure
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

France General , Philip Janiak , Adriaan Voors , Corteria Pharmaceuticals , Menafn Andrew Lloyd Associates , University Medical Centre Groningen Netherlands , Worsening Heart Failure , University Medical Centre Groningen ,

SERENADE: No Benefit, Possible Harm With Macitentan in HFpEF and PAH

In what might prove the swan song for ERAs in HF, SERENADE tried to exclude patients with fluid retention to no avail. ....

Northwestern University , United States , San Francisco , Adriaan Voors , Sanjiv Shah , John Teerlink , University Of California , Md Northwestern University , Md San Francisco Va Medical Center , Phd University Of Groningen , European Society Of Cardiology Heart Failure Congress , European Society , Cardiology Heart Failure Congress ,

Experimental heart failure drug has little impact on exercise tolerance

Heart failure patients taking the investigational drug omecamtiv mecarbil, which has been previously shown to improve long-term outcomes, see little impact on their ability to exercise compared to a placebo, according to a study supported by the Duke Clinical Research Institute. ....

United States , Alain Cohen Solal , Fady Malik , Stuart Kupfer , Lisa Meng , John Teerlink , David Whellan , Marco Metra , Justin Ezekowitz , Michael Felker , Gregory Lewis , Stephen Heitner , Emily Henderson , Adriaan Voors , Piotr Ponikowski , Kieran Docherty , American College Of Cardiology Scientific Sessions , Duke Clinical Research Institute , Duke Clinical Research , Cardiology Scientific , Heart Failure , Multicenter Exercise Tolerance Evaluation , Omecamtiv Mecarbil Related , Increased Contractility , Global Approach , Massachusetts General Hospital ,

Investigational Drug for Heart Failure has Little Impact on Exercise Tolerance

Heart failure patients taking the investigational drug omecamtiv mecarbil, which has been previously shown to improve long-term outcomes, see little impact on t ....

United States , Alain Cohen Solal , Fady Malik , Stuart Kupfer , Lisa Meng , John Teerlink , David Whellan , Marco Metra , Justin Ezekowitz , Michael Felker , Gregory Lewis , Stephen Heitner , Adriaan Voors , Piotr Ponikowski , Kieran Docherty , American College Of Cardiology Scientific Sessions , Duke Clinical Research Institute , Duke Clinical Research , Cardiology Scientific , Heart Failure , Multicenter Exercise Tolerance Evaluation , Omecamtiv Mecarbil Related , Increased Contractility , Global Approach , Massachusetts General Hospital , Eart Failure Exercise Tolerance Heart Disease ,

Empagliflozin benefits adults hospitalised for acute heart failure

Phase III trial shows that adults hospitalised for acute heart failure were 36 percent more likely to experience a clinical benefit if initiated on empagliflozin. ....

Adriaan Voors , Waheed Jamal , Eli Lilly , University Medical Center , European Union , Boehringer Ingelheim , National Readmission Database , Kansas City Cardiomyopathy Questionnaire , Empulse Principal , National Readmission , Corporate Vice President , Cardiometabolic Medicine ,